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ABSTRACT
Background: The pandemic influenza A (H1N1) 2009 [pdm (H1N1) 2009] spread through the world in 2009,
producing a serious epidemic in Japan. Since it was suggested early that asthma is a risk factor for an in-
creased severity of the infection, the Japanese Society of Pediatric Allergy and Clinical Immunology (JSPACI)
organized a working group for countermeasures, and investigated asthmatic children admitted to the hospitals
for pdm (H1N1) 2009 infection.
Methods: An appeal was made on the home page of the JSPACI to medical practitioners to input clinical infor-
mation about asthmatic and non-asthmatic children (0-19 years) admitted to the hospital with pdm (H1N1) 2009
infection.
Results: A total of 862 children (390 with asthma, and 472 without asthma) from 61 medical centers were reg-
istered, and the data of 333 asthmatic children and 388 non-asthmatic children in all were entered in the analy-
ses. The mean age was 7.4 ± 2.9 years in the asthma group and 6.9 ± 3.8 years in the non-asthma group. The
percentage of children admitted for respiratory symptoms was significantly higher in the asthma group than in
the non-asthma group (p < 0.001). There was no significant difference in the frequency of admission to the ICU
or need for mechanical ventilation support between the two groups. No definite trend was detected in the rela-
tionship between the severity of asthma and the intensity of asthma attack. Antiviral drugs were administered
within 24 hours in about 85% of the patients in both groups.
Conclusions: Asthma may not be a risk factor for severe pdm (H1N1) 2009 infection in children.
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INTRODUCTION
The pandemic influenza A (H1N1) 2009 [pdm (H1N1)
2009] infection caused by a new-type influenza virus,
derived from crossing of the molecular features of
North American and Eurasian swine, avian and hu-
man influenza viruses, originated in Mexico in April
2009, and spread rapidly around the world.1-3 In Ja-
pan, the first case of pdm (H1N1) infection was re-
ported in May 2009, although it was not immediately
followed by an epidemic; the serious outbreak began
in the fall of 2009.
There had been reports from the early phase of the
influenza pandemic, that pdm (H1N1) 2009, unlike
conventional influenza viruses, causes serious respi-
ratory symptoms and that the infection is often more
severe in the younger population, including chil-
dren.2,3 And it was also reported that asthma was the
most common underlying disease for the infection.4
Thus, the Japanese Society of Pediatric Allergy and
Clinical Immunology, prompted by the necessity to
take immediate countermeasures for asthmatic chil-
dren, started preparation against the pdm (H1N1)
2009 outbreak in August 2009; as a part of this prepa-
ration, it began an investigation of asthmatic and non-
asthmatic children admitted to the hospital with pdm
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(H1N1) 2009 infection in September 2009. To the
best of our knowledge, this is the first report of analy-
sis focused on asthma as one of the most important
risk factors for pdm (H1N1) 2009 infection.
METHODS
SUBJECTS
Children (0-19 years) diagnosed to have pdm (H1N1)
2009 infection since April 20, 2009, who satisfied the
following 2 conditions:
1) had underlying doctor-diagnosed asthma ac-
cording to the Japanese guideline for childhood
asthma (Japanese Pediatric Guideline for the Treat-
ment and Management of Bronchial Asthma, JPGL)
criteria;
2) required hospitalization for respiratory, neuro-
logical, or other symptoms.
The control group consisted of non-asthmatic chil-
dren (who has no history of asthma or no history of
wheezing for infants) satisfying condition 2).
Children with the following comorbidities were ex-
cluded from the analysis, because the comorbidities
could affect the severity of the pdm (H1N1) 2009 in-
fection, or because its differentiation from asthma
could be difficult:
Symptomatic epilepsy (2 patients), multiple malfor-
mation syndrome (1 patient), leukemia (2 patients,
being treated), idiopathic thrombocytopenia (1 pa-
tient, being treated), type 1 diabetes (2 patients, be-
ing treated), cerebral palsy (3 patients), myopathy (1
patient), tracheostomy (1 patient), nephrotic syn-
drome (3 patients, being treated), congenital adrenal
hyperplasia (1 patient), congenital hydrocephalus (1
patient), juvenile rheumatoid arthritis (1, being
treated with tocilizumab), mucopolysaccharidosis (1
patient), trisomy 21 (1 patient), hypoplastic left heart
syndrome (1 patient), bronchiectasis (1 patient).
METHODS OF STUDY
An appeal was made on the home page of the Japa-
nese Society of Pediatric Allergy and Clinical Immu-
nology to its members, after informing them about
the study, to input replies to the questions posed on
the home page. The items requested to be input
were, essentially, (1) age, (2) sex, (3) duration of the
disease (number of days from onset to admission),
(4) reason for admission (chief complaint), (5) occur-
rence of convulsions during the course of the influ-
enza infection (yesno), (6) occurrence of signs of en-
cephalopathy during the course of the influenza infec-
tion (yesno), (7) occurrence of dyspnea during the
course of the influenza infection (yesno), (8) time of
appearance of dyspnea [if reply to (7) is ‘yes’; how
many hours after symptom onset was dyspnea felt?],
(9) lowest value of SpO2 (room air), (10) needed ad-
mission to ICU (yesno), (11) needed mechanical
ventilation support (yesno), (12) chest X-ray find-
ings, (13) severity of asthma, (14) treatment step in
long-term asthma management, (15) intensity of the
asthma attack [(13)-(15) is not applicable for control
group]. In addition, the respondents were also re-
quested to enter the laboratory data (white blood cell
count, CRP, etc.), content of the treatment, and the
outcome.
The data of patients for whom response entries to
less than 80% of the essential items had been made,
of those whose age was unknown, and of those who
were over 20 years of age were excluded from the
analysis.
METHODS OF ANALYSIS
Using the chi-square test for frequency data and the t-
test for numerical data, the results were compared
between the asthma and non-asthma groups. In re-
gard to the time of appearance of dyspnea, when fe-
ver was taken to mark the onset of the infection, re-
plies to the question of how many hours it took for
the dyspnea to appear after the onset were some-
times given in the negative (because the dyspnea had
occurred prior to the onset of fever). Accordingly, we
determined that the onset was at 48 hours before fe-
ver, event was the appearance of dyspnea, and, if the
event did not occur, observation was discontinued for
5 days after the onset of fever, and censored data
were compared between the two groups by the
Kaplan-Meier method and the log-rank test. As for
the relationship between the level of severity of
asthma and the intensity of the asthma attack, the
level of severity of asthma, based on the clinical fea-
tures and the current treatment step for asthma, and
the intensity of attack were used as categorical vari-
ables, and the trend was tested by the Jonckheere-
Terpstra test. The significance level in all tests was
set at p < 0.05. All the statistical analyses were con-
ducted using the SAS 9.2 and JMP 8.0 software.
RESULTS
SUBJECTS OF THE ANALYSIS
There were 862 registered patients (390 with asthma,
472 without asthma) from 61 medical centers, and, af-
ter exclusion of the patients who did not fulfill the eli-
gibility criteria and those with deficient data input, fi-
nally, a total of 721 patients, including 333 asthmatic
patients and 388 non-asthmatic patients, were entered
into the analyses. The duration of hospitalization of
registered patients was from August 8 to November
27 in 2009. The mean age was 7.4 ± 2.9 years in the
asthma group and 6.9 ± 3.8 years in the non-asthma
group. Figure 1 shows the age distribution. The per-
centage of children under 6 years of age was 26% in
the non-asthma group and 37% in the asthma group.
The malefemale ratio was 1.8 : 1.0 in the non-asthma
group and 2.1 : 1.0 in the asthma group. There was no
significant difference in the malefemale ratio be-
tween the asthma and non-asthma groups (p = 0.209).
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Fig.　1　Age distribution in subjects. The mean age was 7.4 years in the asthma group 
and 6.9 years in the non-asthma group. 
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Fig.　2　Reasons for admission: In asthma group, the majority of reasons for 
admission were respiratory symptoms (88%). In non-asthma group, reasons 
for admission were respiratory symptoms in 48%, and neurological symptoms 
in 32%.
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Neurological symptoms
Digestive symptoms
Respiratory symptoms
32% 48%
88%
REASON FOR ADMISSION
In the asthma group, 88% of the patients were admit-
ted for respiratory symptoms, and in the non-asthma
group, 48% were admitted for respiratory symptoms
and 32% for neurological symptoms (Fig. 2). The per-
centage of patients presenting with respiratory symp-
toms was thus significantly higher in the asthma
group than in the non-asthma group (p < 0.001).
OCCURRENCE OF CONVULSIONS
During the course of influenza, convulsions occurred
in 5% of the patients in the asthma group and 20% of
the patients in the non-asthma group (Fig. 3). Statisti-
cal comparison between the two groups revealed that
the occurence of convulsions was significantly higher
in the non-asthma group than in the asthma group
(p < 0.0001).
OCCURRENCE OF SIGN OF ENCEPHALOPATHY
Encephalopathy was detected in 4% of patients in the
asthma group and 4% of patients in the non-asthma
group, with no significant difference in the incidence
of signs of encephalopathy between the two groups.
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Fig.　3　Occurrence of convulsion. During the course of infl uenza, convulsions 
occurred in 5% of the patients in the asthma group and 20% of the patients in 
the non-asthma group.
AsthmaNon-asthma
Convulsion (+) Convulsion (-)
20%
5%p < 0.0001
Fig.　4　Time of the appearance of dyspnea. Dyspnea occurred in 36% of 
non-asthmatics, and the mean time of appearance was 17.9 hours after 
onset. Dyspnea occurred in 82% of patients with asthma and the mean 
time was 12 hours. Patients complained of dyspnea signifi cantly earlier in 
the asthma group.
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TIME AND FREQUENCY OF APPEARANCE OF
DYSPNEA
Dyspnea occurred in 36.1% of patients in the non-
asthma group, and the mean time of appearance of
dyspnea in the children who developed dyspnea was
17.9 ± 20.9 hours after the onset. Dyspnea occurred
in 82.0% of patients in the asthma group and the mean
time of appearance of dyspnea was 12.1 ± 19.9 hours
after the onset in the asthma group. When no dysp-
nea occurred until the end of 5 days’ (120 hours) ob-
servation after the onset, the reply to the question on
the occurrence of dyspnea was ‘no’ (censored data),
and data were analyzed by the Kaplan-Meier method,
as shown in Figure 4. It became clear from the re-
sults of the log-rank test that patients complained of
dyspnea significantly earlier in the asthma group (p <
0.0001).
ADMISSION TO THE ICU
Admission to ICU was indicated in 7% of patients in
the asthma group and 5% of patients in the non-
asthma group, with no significant difference in the
frequency of ICU admission between the two groups.
NEED FOR MECHANICAL VENTILATION SUP-
PORT
Mechanical ventilation support was needed in 4% of
patients in the asthma group and 1% of patients in the
Pdm (H1N1) 2009 and Asthmatic Children in Japan
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Fig.　5　The SpO2 on room air at admission was 91.3% in the asthma group and 94.3% in the 
non-asthma group.
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Fig.　6　Severity of asthma: the severity based on the clinical features and the cur-
rent treatment step for asthma. The in-remission and intermittent type accounted 
for 63% of asthma group.
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non-asthma group, with no significant difference be-
tween groups in this respect.
SpO2
The minimum value of SpO2 on room air during ad-
mission was 91.3 ± 4.9% in the asthma group and
94.3 ± 3.9% in the non-asthma group (Fig. 5). Statisti-
cal comparison between the two groups revealed that
SpO2 during admission was significantly lower in the
asthma group (p < 0.0001).
SEVERITY OF ASTHMA
In terms of the level of severity of asthma assessed
based on the clinical features and the current treat-
ment step for asthma in the asthma group, the in-
remission and intermittent types were the most fre-
quent (together accounting for 63% of all the cases)
(Fig. 6).
INTENSITY OF ASTHMA ATTACK
There was no acute asthma attack in 35% of the pa-
Katsunuma T et al.
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Fig.　7　Intensity of asthmatic attack: No attack 35%, mild 10%, moderate 33%, 
severe 22%.
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Fig.　8　Relationship between the severity of asthma and the intensity of attack: No defi -
nite trend was detected by Jonckheere-Terpstra test.
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tients, with asthma attacks occurring in 65% of all the
patients in the asthma group (Fig. 7).
RELATIONSHIP BETWEEN THE SEVERITY OF
ASTHMA AND THE INTENSITY OF THE ASTHMA
ATTACK
No definite trend was detected in the intensity of the
asthma attack in the 6 groups classified according to
the asthma severity (in-remission to severe persistent
type) by the Jonckheere-Terpstra test (Fig. 8).
ANTIVIRAL MEDICATION
The mean interval time from the appearance of symp-
toms to the initiation of antiviral drug administration
was 19.7 hours in the non-asthma group and 16.2
hours in the asthma group. Antiviral medication was
started within 24 hours of the onset in about 85% of all
the children in both groups.
DISCUSSION
Data from the American continent, where the pdm
(H1N1) 2009 epidemic had already occurred before it
arrived in Japan, suggested that asthma was the most
common underlying disease seen in both children
and adults infected with the virus.4 Accordingly, the
working group of the Japanese Society of Pediatric
Allergy and Clinical Immunology conducted a survey
of the actual status of pdm (H1N1) 2009 infection in
Japan from September 2009, and performed analyses
from the standpoint of various factors related to
asthma.
Subjects of this analysis were mainly children diag-
nosed to have influenza A by the influenza virus anti-
gen test performed on nasal swab samples using a
Pdm (H1N1) 2009 and Asthmatic Children in Japan
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rapid diagnosis kit, and not all the children were diag-
nosed by the PCR test. However, about 98% of the iso-
lates were the pdm (H1N1) 2009 virus strain during
the influenza season from 2009 through 2010 in Ja-
pan, and the seasonal influenza viruses that had
caused the epidemic until then were scarcely iso-
lated.5 Thus, it may be assumed that almost 100% of
the subjects of the present study were infected with
the pdm (H1N1) 2009 influenza virus.
In this research, we included infants and toddlers
with recurrent wheezing in the analysis as ‘asthmatic
children’, because we consider such young children
with recurrent wheezing as asthma, if they experi-
enced 3 or more independent episodes of wheezing
dyspnea after ruling out other associated diseases
such as obstructive airway diseases, chronic lung dis-
ease, according to JPGL.6
Since all subjects of the present study were hospi-
talized, the influenza virus infection may be assumed
to have been moderate to severe. Age distribution
showed no bias towards infants or young children.
This tendency was in agreement with that reported
by the U.K. study.7 An interesting finding was ob-
tained with respect to the sex distribution, with the
frequency being about twice as high in boys as in
girls. Although the cause for this difference in the sex
predilection is not clear, the sex ratio reported from
most other countries is 1 : 1.4,7 Further studies are
awaited on this issue.
In the study of November 2009 in Japan, asthma
was the most common underlying disease found in
27% of the 220 patients with severe pneumonia
caused by pdm (H1N1) 2009 infection, roughly the
same percentage as that reported from the U.S.8 One
of the major questions at the beginning of the pan-
demic was very simple: “Is the new-type influenza in-
fection exacerbated in correlation with the severity of
asthma?” To this question, the results of the present
study suggested a negative answer. The severity of
the underlying asthma was classified as the in-
remission to mild intermittent type in 63% of the pa-
tients, mild persistent type in 11%, moderate persis-
tent type in 15%, severe persistent type in 10% and se-
verest persistent type in 1% of the hospitalized pa-
tients. This tendency was not significantly different
from that in all children with asthma in Japan9 (data
in Japanese). And the analysis of the relationship be-
tween the severity of asthma and the intensity of
acute asthma attack revealed that no definite trend
was detected among the 6 groups classified accord-
ing to the severity of the asthma (Fig. 8). Based on
the above findings, it would be difficult to assume the
severity of asthma as a factor influencing the severity
of pdm (H1N1) 2009 virus infection.
Dyspnea occurred earlier and more in the asthma
group than in non-asthma group. However, no signifi-
cant differences were seen between groups in the fre-
quency of ICU admission or mechanical ventilation,
which suggests that asthma may not be a risk factor
for severe pdm (H1N1) 2009 infection in children. In
patients with pdm (H1N1) 2009 infection enrolled in a
U.K. study, asthma was the most common underlying
medical condition. However, in an analysis of patients
with serious infection, the severity of the infection
was not related with the presence of underlying
asthma.7 Also in a Singapore study, asthma was a sig-
nificant risk factor for hospitalization by pdm (H1N1)
2009 infection. However, in the serious cases, no sig-
nificant correlation was found.10
Convulsion during the course of the influenza in-
fection occurred more frequently in the non-asthma
group, contrary to our expectation (5% vs. 20%; Fig.4).
According to past bibliographic data, no specific asso-
ciation was detected between asthma and the inci-
dence of seizures.11 And an influence of sampling
bias would be involved. Thus, further study is neces-
sary about the more frequent occurrence of convul-
sions in the non-asthma group observed in the pre-
sent study.
The present analysis drew our attention to the pro-
active administration of antiviral drugs to the patients
with pdm (H1N1) 2009 infection. In an Argentine
study, 17% of hospitalized children needed mechani-
cal ventilation support and 5% died, and antiviral
drugs were administered within 24 hours after the
onset of symptoms to only 13% of these patients.12
There were no deaths in our present case series. In a
WHO report, the mortality rate (deaths per million
population) associated with pdm (H1N1) 2009 was
0.2 as of November 6, 2009 in Japan, the lowest
among 11 countries, including Canada, U.K., Mexico,
U.S., South Africa, Argentina, Australia, Brazil, Chile,
and New Zealand (1.8-14.6).13 Multiple factors may
be involved in this difference in the prognoses, which
were also varied, making reasonable comparison diffi-
cult. However, it would be difficult to rule out the pos-
sibility that proactive administration of antiviral drugs
improved the prognosis of pdm (H1N1) 2009 infec-
tion as a whole, including that in asthmatic children,
in Japan. For the cases analyzed above, systemic cor-
ticosteroids were used for severe respiratory symp-
toms in about 76% of asthmatics, 58% in non-
asthmatics. Since the utility of systemic corticosteroid
therapy for moderate to severe cases affected by pdm
(H1N1) 2009 is still controversial,14,15 further studies
are required.
To summarize, there is scarce evidence to suggest
that asthma is a risk factor for severe pdm (H1N1)
2009 infection. Asthma itself will have to be con-
trolled on an appropriate long-term schedule. In the
presence of pdm (H1N1) 2009 infection, antiviral
medication from an early phase may be considered,
regardless of the presence or absence of underlying
asthma.
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